Activity endpoints
Overall CBR according to RECIST 1.1 was 56.1% (95% CI: 47.3–64.6), and 66.7% (95% CI: 47.9–82.1), 74.2% (95% CI: 57.1–87.0), 59.4% (95% CI: 42.2–75.0), and 27.3% (95% CI: 14.4–43.9) for all included patients and Cohorts 1 to 4, respectively (Fig. With a median follow-up of 16.5 months (range: 0.3-42.9), the median PFS was 5.6 (95% CI: 4.9–6.2), 5.8 (95% CI: 3.1–8.5), 5.5 (95% CI: 2.4–8.7) and 2.4 (95% CI: 2.1–2.8) months, in cohorts 1 to 4 respectively (Fig. 